Navigation Links
Driving Predictability in Clinical Development through Innovation, An Interactive Webinar Hosted by Xtalks
Date:6/11/2013

Toronto, Canada (PRWEB) June 11, 2013

The biopharmaceutical industry is caught between mounting pressure to reduce development costs and the need to ensure better outcomes from clinical trials.

Generics, lower approval rates, and global testing requirements have increased drug development costs. Yet, outcomes have remained uncertain in terms of both regulatory approval and market acceptance, and large payers continue to exert downward pressure on prices.

Although the stakes continue to increase, changing regulatory guidelines and advanced data collection methods are creating new opportunities to streamline and better focus the clinical trial process. This has the potential to reduce costs, improve trial predictability and accelerate the time it takes to bring a compound to market.

This webinar will explore the direction clinical research is headed and the role innovation plays in its new course. An expert panel, featuring speakers from INC Research, will share insights on how adapting the process of clinical development at strategic points and implementing new strategies can result in reduced cost and development time. Speakers will also discuss the value of optimizing protocols against development needs and the value of a holistic, end-to-end, approach to optimize trial delivery.

This webinar will present operational plans that are fit for purpose and that leverage leading technology for greater efficiency and predictability in conducting clinical research. Join us for an exciting, interactive discussion!

To learn more about the event, visit:
http://www.xtalks.com/clinical-process-innovation.ashx

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year, thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com/ContactUs.ashx

Contact:
Karen Lim 416-977-6555 ext. 227
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/6/prweb10818133.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. GenScript Rush Gene Synthesis - Driving Molecular Biology Research Faster
2. Lupus Research Institute Awards $3.6 Million for Novel Studies Driving Wide-Ranging New Science in Lupus
3. Andain Inc. Announces 2,000 Units Initial Production of the Breakthrough Miniature Disposable Insulin Pump for Use in Clinical Trials for Type-I and Type-II Diabetes
4. Clinical Development, Contracts and Outsourcing in MENA & APAC, New Webinar Hosted by Xtalks
5. Clinovo Sponsors the First Outsourcing in Clinical Trials: Medical Devices & Diagnostics Conference, June 12-13, 2013 in Saint Paul, Minnesota
6. SentoClone International AB Significantly Strengthens its Global Patent Portfolio Covering its Clinical Stage Sentinel Node-derived CD4 T-cell Cancer Therapy
7. Actinium Pharmaceuticals Acute Myeloid Leukemia Clinical Data to be Presented Today at 8th International Symposium on Targeted Alpha Therapy Conference
8. Patheon to Host Complimentary Seminar on “Formulation, Funding and First-in-Man: A Stepwise Guide to Clinical Success”
9. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
10. National Brain Tumor Society Responds to Results of Avastin Clinical Trials
11. AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... Cancer experts from Austria, Hungary, Switzerland, and ... new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has just published ... , Biomarkers are components in the blood, tissue or body fluids that ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... announced the funding of a Sponsored Research Agreement ... circulating tumor cells (CTCs) from cancer patients.  The ... in CTC levels correlate with clinical outcomes in ... These data will then be employed to support ...
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
Breaking Biology Technology:
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
(Date:3/23/2016)... 23, 2016 ... Gesichts- und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler ... mit SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie ... die Möglichkeit angeboten, im Rahmen mobiler Apps ...
Breaking Biology News(10 mins):